CAND1

Across TCGA pan-cancer cohorts, CAND1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CAND1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CAND1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CAND1 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where CAND1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CAND1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.242	<.001	10	view →
HNSC	All	IV	+0.320	<.001	9	view →
PDAC	Male	II,III,IV	+0.305	<.001	8	view →
LSCC	Female	All	+0.245	<.001	7	view →
LUAD	Male	All	+0.170	<.001	7	view →
COAD	Male	II,III,IV	−0.118	<.001	5	view →
OV	All	All	+0.418	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CAND1–CCRCC

Open the CCRCC breakdown →